Protagonist Therapeutics (PTGX) Operating Income (2017 - 2025)
Historic Operating Income for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$46.4 million.
- Protagonist Therapeutics' Operating Income fell 1198.47% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 8725.25%. This contributed to the annual value of $252.8 million for FY2024, which is 36998.14% up from last year.
- According to the latest figures from Q3 2025, Protagonist Therapeutics' Operating Income is -$46.4 million, which was down 1198.47% from -$42.0 million recorded in Q2 2025.
- In the past 5 years, Protagonist Therapeutics' Operating Income registered a high of $206.3 million during Q1 2024, and its lowest value of -$46.4 million during Q3 2025.
- Moreover, its 5-year median value for Operating Income was -$36.0 million (2023), whereas its average is -$10.8 million.
- In the last 5 years, Protagonist Therapeutics' Operating Income plummeted by 33651.57% in 2021 and then skyrocketed by 67274.65% in 2024.
- Protagonist Therapeutics' Operating Income (Quarter) stood at -$37.0 million in 2021, then increased by 1.35% to -$36.5 million in 2022, then skyrocketed by 163.12% to $23.0 million in 2023, then skyrocketed by 450.05% to $126.8 million in 2024, then crashed by 136.62% to -$46.4 million in 2025.
- Its Operating Income was -$46.4 million in Q3 2025, compared to -$42.0 million in Q2 2025 and -$19.3 million in Q1 2025.